Potential role of miR-100 in cancer diagnosis, prognosis, and therapy

详细信息    查看全文

• 作者：Chu Qin (1)
  Ru-Yi Huang (1)
  Zhao-Xia Wang (2)
  
  1. Department of Clinical Medicine ; The First Medical college of Nanjing Medical University ; Nanjing ; 210029 ; Jiangsu ; People鈥檚 Republic of China
  2. Department of Oncology ; The Second Affiliated Hospital ; Nanjing Medical University ; 121 Jiangjiayuan Road ; Nanjing ; 210011 ; Jiangsu ; People鈥檚 Republic of China
  
• 关键词：Non ; coding RNA ; miR ; 100 ; Human cancer ; Diagnostic ; Prognostic ; Biomarker
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：36
• 期：3
• 页码：1403-1409
• 全文大小：190 KB
• 参考文献：1. Costa, PM, Pedroso, DLM (2013) MicroRNAs as molecular targets for cancer therapy: on the modulation of microrna expression. Pharmaceuticals (Basel) 6: pp. 1195-220 CrossRef
  2. Ryan, BM, Robles, AI, Harris, CC (2010) Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10: pp. 389-402 CrossRef
  3. Dela, CF, Matushansky, I (2011) MicroRNAs in chromosomal translocation-associated solid tumors: learning from sarcomas. Discov Med 12: pp. 307-17
  4. Hertel, J, Bartschat, S, Wintsche, A, Otto, C, Stadler, PF (2012) Evolution of the let-7 microRNA family. RNA Biol 9: pp. 231-41 CrossRef
  5. Heimberg, AM, Sempere, LF, Moy, VN, Donoghue, PC, Peterson, KJ (2008) MicroRNAs and the advent of vertebrate morphological complexity. Proc Natl Acad Sci U S A 105: pp. 2946-50 CrossRef
  6. Carthew, RW, Sontheimer, EJ (2009) Origins and mechanisms of miRNAs and siRNAs. Cell 136: pp. 642-55 CrossRef
  7. Grishok, A, Pasquinelli, AE, Conte, D, Li, N, Parrish, S, Ha, I (2001) Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 106: pp. 23-34 CrossRef
  8. Xu, C, Zeng, Q, Xu, W, Jiao, L, Chen, Y, Zhang, Z (2013) MiRNA-100 inhibits human bladder urothelial carcinogenesis by directly targeting mTOR. Mol Cancer Ther 12: pp. 207-19 CrossRef
  9. Sun, J, Chen, Z, Tan, X, Zhou, F, Tan, F, Gao, Y (2013) MicroRNA-99a/100 promotes apoptosis by targeting mtor in human esophageal squamous cell carcinoma. Med Oncol 30: pp. 411 CrossRef
  10. Zhu, Z, Wang, CP, Zhang, YF, Nie, L (2014) MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR. Asian Pac J Cancer Prev 15: pp. 917-23 CrossRef
  11. Huang, JS, Egger, ME, Grizzle, WE, McNally, LR (2013) MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells. Biotech Histochem 88: pp. 397-402 CrossRef
  12. Li, XJ, Luo, XQ, Han, BW, Duan, FT, Wei, PP, Chen, YQ (2013) MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways. Br J Cancer 109: pp. 2189-98 CrossRef
  13. Gebeshuber, CA, Martinez, J (2013) Mir-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling. Oncogene 32: pp. 3306-10 CrossRef
  14. Chen, Z, Jin, Y, Yu, D, Wang, A, Mahjabeen, I, Wang, C (2012) Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma. Oral Oncol 48: pp. 686-91 CrossRef
  15. Blick, C, Ramachandran, A, Wigfield, S, McCormick, R, Jubb, A, Buffa, FM (2013) Hypoxia regulates FGFR3 expression via HIF-1alpha and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer. Br J Cancer 109: pp. 50-9 CrossRef
  16. Tovar, V, Alsinet, C, Villanueva, A, Hoshida, Y, Chiang, DY, Sole, M (2010) IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 52: pp. 550-9 CrossRef
  17. Li, BH, Zhou, JS, Ye, F, Cheng, XD, Zhou, CY, Lu, WG (2011) Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein. Eur J Cancer 47: pp. 2166-74 CrossRef
  18. Petrelli, A, Perra, A, Schernhuber, K, Cargnelutti, M, Salvi, A, Migliore, C (2012) Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene 31: pp. 4517-26 CrossRef
  19. Feng, B, Wang, R, Chen, LB (2012) MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting PLK1. Cancer Lett 317: pp. 184-91 CrossRef
  20. Shi, W, Alajez, NM, Bastianutto, C, Hui, AB, Mocanu, JD, Ito, E (2010) Significance of PLK1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer 126: pp. 2036-48
  21. Liu, J, Lu, KH, Liu, ZL, Sun, M, De, W, Wang, ZX (2012) MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. BMC Cancer 12: pp. 519 CrossRef
  22. Mueller, AC, Sun, D, Dutta, A (2013) The miR-99 family regulates the DNA damage response through its target snf2h. Oncogene 32: pp. 1164-72 CrossRef
  23. Huang, J, Gao, K, Lin, J, Wang, Q (2014) MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61. Tumour Biol 35: pp. 1095-100 CrossRef
  24. Zheng, YS, Zhang, H, Zhang, XJ, Feng, DD, Luo, XQ, Zeng, CW (2012) Mir-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene 31: pp. 80-92 CrossRef
  25. Szabo, DR, Luconi, M, Szabo, PM, Toth, M, Szucs, N, Horanyi, J (2014) Analysis of circulating microRNAs in adrenocortical tumors. Lab Invest 94: pp. 331-9 CrossRef
  26. Wu, C, Wang, C, Guan, X, Liu, Y, Li, D, Zhou, X (2014) Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma. PLoS One 9: pp. e92292 CrossRef
  27. Wong, TS, Liu, XB, Wong, BY, Ng, RW, Yuen, AP, Wei, WI (2008) Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 14: pp. 2588-92 CrossRef
  28. Torres, A, Torres, K, Pesci, A, Ceccaroni, M, Paszkowski, T, Cassandrini, P (2012) Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma@@. BMC Cancer 12: pp. 369 CrossRef
  29. Cazzoli, R, Buttitta, F, Nicola, M, Malatesta, S, Marchetti, A, Rom, WN (2013) MicroRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol 8: pp. 1156-62 CrossRef
  30. Ratert, N, Meyer, HA, Jung, M, Lioudmer, P, Mollenkopf, HJ, Wagner, I (2013) MiRNA profiling identifies candidate miRNAs for bladder cancer diagnosis and clinical outcome. J Mol Diagn 15: pp. 695-705 CrossRef
  31. Oliveira, JC, Brassesco, MS, Morales, AG, Pezuk, JA, Fedatto, PF, Da, SG (2011) MicroRNA-100 acts as a tumor suppressor in human bladder carcinoma 5637 cells. Asian Pac J Cancer Prev 12: pp. 3001-4
  32. Dip, N, Reis, ST, Timoszczuk, LS, Viana, NI, Piantino, CB, Morais, DR (2012) Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile. J Urol 188: pp. 1951-6 CrossRef
  33. LaConti, JJ, Shivapurkar, N, Preet, A, Deslattes, MA, Peran, I, Kim, SE (2011) Tissue and serum microRNAs in the kras (g12d) transgenic animal model and in patients with pancreatic cancer. PLoS One 6: pp. e20687 CrossRef
  34. Luo, D, Wilson, JM, Harvel, N, Liu, J, Pei, L, Huang, S (2013) A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells. J Transl Med 11: pp. 57 CrossRef
  35. Zhong, S, Li, W, Chen, Z, Xu, J, Zhao, J (2013) MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene 531: pp. 8-14 CrossRef
  36. Peng, DX, Luo, M, Qiu, LW, He, YL, Wang, XF (2012) Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep 27: pp. 1238-44
  37. Ng, WL, Yan, D, Zhang, X, Mo, YY, Wang, Y (2010) Over-expression of miR-100 is responsible for the low-expression of ATM in the human glioma cell line: M059J. DNA Repair (Amst) 9: pp. 1170-5 CrossRef
  38. Siegel, R, Ma, J, Zou, Z, Jemal, A (2014) Cancer statistics, 2014. CA Cancer J Clin 64: pp. 9-29 CrossRef
  39. Zhou, J, Song, T, Gong, S, Zhong, M, Su, G (2010) MicroRNA regulation of the expression of the estrogen receptor in endometrial cancer. Mol Med Rep 3: pp. 387-92
  40. Vriens, MR, Weng, J, Suh, I, Huynh, N, Guerrero, MA, Shen, WT (2012) MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer 118: pp. 3426-32 CrossRef
  41. Zhang, C, Wang, C, Chen, X, Yang, C, Li, K, Wang, J (2010) Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 56: pp. 1871-9 CrossRef
  42. Oliveira, JC, Scrideli, CA, Brassesco, MS, Morales, AG, Pezuk, JA, Queiroz, RP (2012) Differential miRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features. Leuk Res 36: pp. 293-8 CrossRef
  43. Huang, L, Lin, JX, Yu, YH, Zhang, MY, Wang, HY, Zheng, M (2012) Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One 7: pp. e33762 CrossRef
  44. Leite, KR, Tomiyama, A, Reis, ST, Sousa-Canavez, JM, Sanudo, A, Camara-Lopes, LH (2013) MicroRNA expression profiles in the progression of prostate cancer鈥攆rom high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol 31: pp. 796-801 CrossRef
  45. Wang, S, Xue, S, Dai, Y, Yang, J, Chen, Z, Fang, X (2012) Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol 7: pp. 159 CrossRef
  46. Chen, J, Zheng, B, Wang, C, Chen, Y, Du, C, Zhao, G (2013) Prognostic role of microRNA-100 in various carcinomas: evidence from six studies. Tumour Biol 35: pp. 3067-71 CrossRef
  47. Leite, KR, Sousa-Canavez, JM, Reis, ST, Tomiyama, AH, Camara-Lopes, LH, Sanudo, A (2011) Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol 29: pp. 265-9 CrossRef
  48. Leite, KR, Tomiyama, A, Reis, ST, Sousa-Canavez, JM, Sanudo, A, Dall鈥橭glio, MF (2011) MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol 185: pp. 1118-22 CrossRef
  49. Chang, L, Graham, PH, Hao, J, Bucci, J, Cozzi, PJ, Kearsley, JH (2014) Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer Metastasis Rev 33: pp. 469-96 CrossRef
  50. Wang, M, Ren, D, Guo, W, Wang, Z, Huang, S, Du, H (2014) Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting argonaute 2. Int J Oncol 45: pp. 362-72
  51. Brennan, P, Hainaut, P, Boffetta, P (2011) Genetics of lung-cancer susceptibility. Lancet Oncol 12: pp. 399-408 CrossRef
  52. Goldstraw, P, Ball, D, Jett, JR, Chevalier, T, Lim, E, Nicholson, AG (2011) Non-small-cell lung cancer. Lancet 378: pp. 1727-40 CrossRef
  53. Xiao, F, Bai, Y, Chen, Z, Li, Y, Luo, L, Huang, J (2014) Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100. Eur J Cancer 50: pp. 1541-54 CrossRef
  54. Zhang, Y, Shi, ZL, Yang, X, Yin, ZF (2014) Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis. World J Gastroenterol 20: pp. 142-7 CrossRef
  55. Chen, P, Zhao, X, Ma, L (2013) Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem 383: pp. 49-58 CrossRef
  56. Zhang, H, Luo, XQ, Zhang, P, Huang, LB, Zheng, YS, Wu, J (2009) MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One 4: pp. e7826 CrossRef
  57. Bai, J, Guo, A, Hong, Z, Kuai, W (2012) Upregulation of microRNA-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia. Onco Targets Ther 5: pp. 213-9
  58. Nagaraja, AK, Creighton, CJ, Yu, Z, Zhu, H, Gunaratne, PH, Reid, JG (2010) A link between miR-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 24: pp. 447-63 CrossRef
  59. Deng, L, Shang, L, Bai, S, Chen, J, He, X, Trevino, RM (2014) MicroRNA100 inhibits self-renewal of breast cancer stem-like cells and breast tumor development. Cancer Res 74: pp. 6648-60 CrossRef
  60. Chen, P, Xi, Q, Wang, Q, Wei, P (2014) Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in colorectal cancer. Med Oncol 31: pp. 235 CrossRef
  61. Kota, J, Chivukula, RR, O鈥橠onnell, KA, Wentzel, EA, Montgomery, CL, Hwang, HW (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: pp. 1005-17 CrossRef
  62. Li, Z, Li, X, Yu, C, Wang, M, Peng, F, Xiao, J (2014) MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3. Tumour Biol 35: pp. 11751-9 CrossRef
  63. Bera, A, VenkataSubbaRao, K, Manoharan, MS, Hill, P, Freeman, JW (2014) A miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer. PLoS One 9: pp. e106343 CrossRef
  
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

MicroRNAs (miRNAs) are small non-coding RNAs that function by base pairing with messenger RNAs, thereby regulating protein expression. Functional studies indicate that miRNAs are involved in the regulation of almost every biological pathway. Moreover, changes in miRNA expression are associated with several human pathologies, including cancer. Dysregulation and aberrant expression of microRNA-100 (miR-100) have been reported to be involved in tumorigenesis and tumor progression of several cancer types, suggesting that miR-100 might serve as a diagnostic and/or prognostic marker for human malignancy. In this review, we summarize the potential application of miR-100 in cancer treatment and as a new molecular marker for cancer prognosis and diagnosis. We will provide a brief introduction to miR-100 and discuss its role as a non-invasive biomarker and a potential therapeutic target in human cancers.